reports
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
ACN ACCENTURE PLC CLASS A
WK WORKIVA
WDAY WORKDAY INC. CLASS A
THRM GENTHERM INCORPORATED
SXT SENSIENT TECHNOLOGIES CORPORATION
SFM SPROUTS FARMERS MARKETS INC.
NSP INSPERITY INC.
HTGC HERCULES CAPITAL INC.
GPC GENUINE PARTS COMPANY
FELE FRANKLIN ELECTRIC CO. INC.
EXTR EXTREME NETWORKS INC.
EXPE EXPEDIA GROUP INC.
CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION CLASS A
CRY CRYOLIFE INC.
CPRT COPART INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ATRC ATRICURE INC.
STN. STANTEC INC
TLX TALANX AG
FLTR FLUTTER ENTERTAINMENT PLC
BRO BROWN & BROWN INC.
SLM SLM CORP
TREE LENDINGTREE INC.
USLM U.S. LIME & MINERALS
WCN WASTE CONNECTIONS INC.
GIB.A CGI INC. CLASS A
CHWY CHEWY INC. CLASS A
QS QUANTUMSCAPE
SOFI SOFI TECHNOLOGIES INC
BWMN BOWMAN CONSULTING GROUP LTD
TPG TPG INC
SMR NUSCALE POWER CORP
ALAB ASTERA LABS INC
CAI CARIS LIFE SCIENCES INC
PTRN PATTERN GROUP INC.
LCID LUCID GROUP INC.
GDYN GRID DYNAMICS HOLDINGS INC.
APPE1 ASAN PARDAKHT PERSIAN ORD
Outlook Therapeutics Expands European Footprint with Exclusive Commerc...
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partnerMediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab gamma) in SwitzerlandPartnership advances European commercial expansion strategy, with LYTENAVA™ (bevacizumab gamma) expected to launch in Switzerland in 2027 ISELIN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- (Nasda...
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial ...
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026Additional European launches expected in 2026Type A meeting request submitted to the U.S. Food and Drug Administration for ONS-5010 ISELIN, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for ...
Brown & Brown, Inc. acquires the assets of The Protectorate Group Insu...
Brown & Brown, Inc. acquires the assets of The Protectorate Group Insurance Agency, Inc., doing business as American Adventure Insurance DAYTONA BEACH, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- J. Scott Penny, chief acquisitions officer of Brown & Brown, Inc. (NYSE:BRO), and Paul Bender, the owner of The Protectorate Group Insurance Agency, Inc., doing business as American Adventure Insurance (“American Adventure”), today announced that Brown & Brown Dealer Services (“BBDS”) has acquired the assets of American Adventure. American Adventure specializes in providing insurance solutions at th...
Brown & Brown announces appointment of Dorothea (Dori) Henderson as ch...
Brown & Brown announces appointment of Dorothea (Dori) Henderson as chief information technology officer DAYTONA BEACH, Fla., Feb. 16, 2026 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE: BRO) (“the Company”) is pleased to announce that Dorothea (“Dori”) Henderson has been appointed chief information technology officer. She will lead the company’s enterprise technology strategy and oversee initiatives to improve digital capabilities and enhance the technology experience for teammates and customers. In this role, Henderson will work with segment and functional leaders to enhance teammate t...
Brown & Brown, Inc. announces entry into accelerated share repurchase ...
Brown & Brown, Inc. announces entry into accelerated share repurchase program DAYTONA BEACH, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE: BRO) (the “Company”) today announced that it has entered into an accelerated share repurchase program (ASR) with Bank of America, N.A. for $250 million of the Company's common stock. The ASR is part of the Company’s board-approved $1.5 billion share repurchase authorization announced on October 22, 2025. About Brown & Brown, Inc. Brown & Brown, Inc. (NYSE: BRO) is a leading insurance brokerage firm delivering comprehensive and cu...
Brown & Brown 2026 Market Trends Report sees softening commercial rate...
Brown & Brown 2026 Market Trends Report sees softening commercial rates, more capacity, carrier competition Suggests careful preparation, positive claims history can favor buyer renewal DAYTONA BEACH, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE: BRO) (“the Company”) today announced the release of the 2026 edition of its Market Trends report. A comprehensive analysis of emerging market shifts, this year’s report finds that rate conditions are shifting in favor of buyers who prepare thoroughly for the renewal process and have a positive claims history. The report als...
Outlook Therapeutics Submits Type A Meeting Request to FDA Following C...
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has submitted a Type A meeting request to the U.S. Food and Drug Administration (FDA) following receipt of a Complete Response Letter (CRL) dated December 30, 2025, regarding the Company’s Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of ...
Bread Financial Provides Performance Update for January 2026
Bread Financial Provides Performance Update for January 2026 COLUMBUS, Ohio, Feb. 10, 2026 (GLOBE NEWSWIRE) -- (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions to millions of U.S. consumers, provided a performance update. The following tables present the Company’s Net principal loss rate and Delinquency rate for the periods indicated: For themonth endedJanuary 31, 2026 For themonth endedJanuary 31, 2025 (dollars in millions)End-of-period credit card and other loans$18,386 $18,366 Average credit card and oth...
Bread Financial to Participate in the UBS Financial Services Conferenc...
Bread Financial to Participate in the UBS Financial Services Conference COLUMBUS, Ohio, Feb. 04, 2026 (GLOBE NEWSWIRE) -- (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions, today announced the company’s participation in the UBS Financial Services Conference on Wednesday, February 11. Bread Financial EVP and Chief Financial Officer Perry Beberman will participate in a fireside chat. The fireside chat will take place at 12:10 p.m. ET and will be broadcast live . The fireside chat can also be accessed through B...
Bread Financial to Participate in the Bank of America 2026 Financial S...
Bread Financial to Participate in the Bank of America 2026 Financial Services Conference COLUMBUS, Ohio, Feb. 03, 2026 (GLOBE NEWSWIRE) -- (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions, today announced the company’s participation in the Bank of America 2026 Financial Services Conference on Tuesday, February 10. Bread Financial President and Chief Executive Officer Ralph Andretta, along with EVP and Chief Financial Officer Perry Beberman will participate in a fireside chat. The fireside chat will take plac...
- Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TSLA TESLA INC
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
NFLX NETFLIX INC.
FRX_CN FENNEC PHARMACEUTICALS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
GOSS GOSSAMER BIO
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ZNTL KEROS THERAPEUTICS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
PRAX LARIMAR THERAPEUTICS INC
U PRAXIS PRECISION MEDICINES
TVTX UNITY SOFTWARE
DASH TRAVERE THERAPEUTICS INC
VRDN DOORDASH
PLTK VIRIDIAN THERAPEUTICS INC
RBLX PLAYTIKA HOLDING
DAWN ROBLOX
STX DAY ONE BIOPHARMACEUTICALS INC
APP SEAGATE TECHNOLOGY HLDGS PLC
GFS APPLOVIN CORP
GMTX GLOBALFOUNDRIES INC
TYRA GEMINI THERAPEUTICS INC
EWTX TYRA BIOSCIENCES INC
SLDB EDGEWISE THERAPEUTICS INC
APGE SOLID BIOSCIENCES INC
DNTH APOGEE THERAPEUTICS INC
CGON DIANTHUS THERAPEUTICS INC
ORKA CG ONCOLOGY INC
BCAX ORUKA THERAPEUTICS INC
ZBIO BICARA THERAPEUTICS INC.
TLX ZENAS BIOPHARMA INC.
MAZE TELIX PHARMACEUTICALS LIMITED
JBIO MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Robert Driscoll
- Thomas Yip
- Yun Zhong
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
GMTX GEMINI THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
SLDB SOLID BIOSCIENCES INC
APGE APOGEE THERAPEUTICS INC
DNTH DIANTHUS THERAPEUTICS INC
ORKA ORUKA THERAPEUTICS INC
BCAX BICARA THERAPEUTICS INC.
ZBIO ZENAS BIOPHARMA INC.
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
JBIO JADE BIOSCIENCES INC
Bread Financial Provides Performance Update for December 2025
Bread Financial Provides Performance Update for December 2025 COLUMBUS, Ohio, Jan. 29, 2026 (GLOBE NEWSWIRE) -- (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions to millions of U.S. consumers, provided a performance update. The following tables present the Company’s net loss rate and delinquency rate for the periods indicated: For themonth endedDecember 31, 2025 For thethree months endedDecember 31, 2025 (dollars in millions)End-of-period credit card and other loans$18,805 $18,805 Average credit card and ot...
Bread Financial Reports Fourth Quarter and Full Year 2025 Results
Bread Financial Reports Fourth Quarter and Full Year 2025 Results COLUMBUS, Ohio, Jan. 29, 2026 (GLOBE NEWSWIRE) -- (NYSE: BFH), a tech-forward financial services company that provides simple, flexible payment, lending and saving solutions, today announced its fourth quarter and full year 2025 financial results. All earnings-related materials are now available at the company’s investor relations website, . Bread Financial President and Chief Executive Officer Ralph Andretta and Chief Financial Officer Perry Beberman will host a conference call at 8:30 a.m. ET today to discuss results. A...
Bread Financial Declares Dividends on Preferred and Common Stock
Bread Financial Declares Dividends on Preferred and Common Stock COLUMBUS, Ohio, Jan. 29, 2026 (GLOBE NEWSWIRE) -- . (NYSE: BFH), a tech-forward financial services company that provides simple, flexible payment, lending and saving solutions, today announced that its Board of Directors declared quarterly dividends on its preferred and common stock for the first quarter of 2026. On the Company’s 8.625% Non-Cumulative Perpetual Preferred Stock, Series A (NYSE: BFH-PrA), the Board of Directors declared a quarterly cash dividend of $26.35 per share (equivalent to $0.65875 per depositary share...
Brown & Brown, Inc. announces fourth quarter 2025 results, including t...
Brown & Brown, Inc. announces fourth quarter 2025 results, including total revenues of $1.6 billion, an increase of 35.7%; Organic Revenue decrease of 2.8%; diluted net income per share of $0.59; and Diluted Net Income Per Share - Adjusted of $0.93 DAYTONA BEACH, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE:BRO) (the "Company") announced its unaudited financial results for the fourth quarter and full year of 2025. For the fourth quarter ended December 31, 2025, the Company achieved: Total revenues of $1.6 billion, increasing $423 million, or 35.7%, compared to the f...
Brown & Brown mourns the passing of Chief Legal Officer Robert Mathis
Brown & Brown mourns the passing of Chief Legal Officer Robert Mathis DAYTONA BEACH, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- It is with profound sadness that Brown & Brown, Inc. (NYSE: BRO) (“the Company”) announces the passing of Chief Legal Officer, Robert Mathis. A great friend and teammate, Robert was a dynamic leader, an exceptional attorney and keen legal mind. He brought clarity to complexity, steadiness to challenging moments and genuine care to every relationship. His impact on our organization and on all who had the privilege to work alongside him is immeasurable. “Rob set the...
Brown & Brown launches fully integrated National Healthcare Practice
Brown & Brown launches fully integrated National Healthcare Practice An integrated national practice delivering comprehensive healthcare risk, insurance and brokerage solutions DAYTONA BEACH, Fla., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE: BRO) (“the Company”) today announced the launch of a fully integrated, all-lines National Healthcare Practice — Brown & Brown Healthcare. This major step brings together more than 140 seasoned professionals into a specialized team dedicated to delivering comprehensive, innovative risk solutions for the full spectrum of healthcare o...
Brown & Brown, Inc. announces quarterly cash dividend
Brown & Brown, Inc. announces quarterly cash dividend DAYTONA BEACH, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE: BRO) announces that the board of directors has declared a regular quarterly cash dividend of $0.165 per share. The dividend is payable on February 11, 2026, to shareholders of record on February 4, 2026. About Brown & Brown, Inc. Brown & Brown, Inc. (NYSE: BRO) is a leading insurance brokerage firm delivering comprehensive and customized insurance solutions and specialization since 1939. With a global presence spanning 700+ locations and a team of more...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.